Organon (OGN) Appoints Ramona A. Sequeira to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
April 15, 2025 5:00 PM EDTJERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) a global healthcare company with a focus on womens health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organons Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Boards Talent Committee. In connection with Ms. Sequeiras appointment, the size of Organons Board will be expanded to 12 directors.
Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company... More
